** Shares of Danaher DHR.N rise 1.7% to $243.86 premarket
** Life sciences co said on Monday it expects Q4 revenue to increase in low-single digit percent range year-over-year
** Preliminary results indicate continued but expected recovery in co's bioprocessing unit, brokerage Leerink Partners says
** "We continue to see DHR as a sector leader and an M&A compounder/operator with a market-leading franchise in bioprocessing," Leerink says
** DHR fell 0.8% in 2024
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))